$LPTX
LEAP THERAPEUTICS, INC.

2021 Q4 Form 10-K Financial Statement

#000110465922032638 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $375.0K $1.500M $380.0K
YoY Change -1.32% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.793M $10.77M $2.430M
YoY Change 14.94% 11.91% -6.54%
% of Gross Profit
Research & Development $8.070M $32.16M $5.100M
YoY Change 58.24% 57.47% -10.05%
% of Gross Profit
Depreciation & Amortization $8.000K $29.00K $0.00
YoY Change -14.71% -100.0%
% of Gross Profit
Operating Expenses $10.86M $42.93M $7.530M
YoY Change 44.26% 42.9% -8.95%
Operating Profit -$41.43M
YoY Change 45.16%
Interest Expense $34.00K $41.00K $550.0K
YoY Change -93.82% 5.13% 103.7%
% of Operating Profit
Other Income/Expense, Net -$358.0K $1.226M -$110.0K
YoY Change 225.45% 433.04%
Pretax Income -$10.81M -$40.61M -$6.710M
YoY Change 61.13% 47.59% -16.13%
Income Tax -$24.00K -$24.00K $0.00
% Of Pretax Income
Net Earnings -$10.79M -$40.59M -$6.710M
YoY Change 60.77% 47.51% -16.13%
Net Earnings / Revenue -2876.8% -2705.8% -1765.79%
Basic Earnings Per Share -$0.47
Diluted Earnings Per Share -$125.7K -$0.47 -$112.5K
COMMON SHARES
Basic Shares Outstanding 88.32M 85.83M
Diluted Shares Outstanding 85.83M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.9M $114.9M $52.07M
YoY Change 120.7% 120.7% 1238.56%
Cash & Equivalents $114.9M $114.9M $52.07M
Short-Term Investments
Other Short-Term Assets $769.0K $769.0K $130.0K
YoY Change 491.54% 491.54% -23.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $116.9M $116.9M $52.27M
YoY Change 123.58% 123.6% 1132.88%
LONG-TERM ASSETS
Property, Plant & Equipment $36.00K $495.0K $65.00K
YoY Change -44.62% -16.1% -94.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $542.0K $1.500M
YoY Change -94.0% -63.87% -27.18%
Total Long-Term Assets $1.037M $1.037M $2.097M
YoY Change -50.55% -50.62% -34.67%
TOTAL ASSETS
Total Short-Term Assets $116.9M $116.9M $52.27M
Total Long-Term Assets $1.037M $1.037M $2.097M
Total Assets $117.9M $117.9M $54.37M
YoY Change 116.86% 116.87% 629.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.189M $4.189M $2.717M
YoY Change 54.18% 54.01% -40.55%
Accrued Expenses $5.366M $5.798M $2.747M
YoY Change 95.34% 83.48% -29.92%
Deferred Revenue $1.500M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.987M $9.987M $7.372M
YoY Change 35.47% 35.51% -13.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.00K $37.00K $350.0K
YoY Change -89.43% -89.43% -50.7%
Total Long-Term Liabilities $37.00K $37.00K $350.0K
YoY Change -89.43% -89.43% -50.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.987M $9.987M $7.372M
Total Long-Term Liabilities $37.00K $37.00K $350.0K
Total Liabilities $10.02M $10.02M $7.720M
YoY Change 29.84% 29.84% -16.09%
SHAREHOLDERS EQUITY
Retained Earnings -$263.6M -$223.0M
YoY Change 18.2%
Common Stock $88.00K $60.00K
YoY Change 46.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.9M $107.9M $46.65M
YoY Change
Total Liabilities & Shareholders Equity $117.9M $117.9M $54.37M
YoY Change 116.86% 116.87% 629.81%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$10.79M -$40.59M -$6.710M
YoY Change 60.77% 47.51% -16.13%
Depreciation, Depletion And Amortization $8.000K $29.00K $0.00
YoY Change -14.71% -100.0%
Cash From Operating Activities -$10.72M -$35.16M -$5.990M
YoY Change 78.9% 35.44% 1.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 755.0K 98.04M 0.000
YoY Change 32.49% -100.0%
NET CHANGE
Cash From Operating Activities -10.72M -35.16M -5.990M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 755.0K 98.04M 0.000
Net Change In Cash -9.961M 62.85M -5.990M
YoY Change 66.29% 30.44% 1.53%
FREE CASH FLOW
Cash From Operating Activities -$10.72M -$35.16M -$5.990M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$10.72M -$35.16M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85825283
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59327713
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001509745
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59657742
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88318454
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37990
CY2021 dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B1-1
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
714-0360
CY2021 dei Trading Symbol
TradingSymbol
LPTX
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
86766207000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88318454
CY2021 dei Auditor Firm
AuditorFirmId
274
CY2021 dei Auditor Name
AuditorName
EisnerAmper LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114916000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52071000
CY2021Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
1189000
CY2020Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
73000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
769000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
116874000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
52274000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
528000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
159000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
179000
CY2020Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
345000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
293000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
980000
CY2021Q4 us-gaap Assets
Assets
117911000
CY2020Q4 us-gaap Assets
Assets
54371000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4189000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2717000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2747000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1500000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
408000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9987000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7372000
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
204000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
144000
CY2021Q4 us-gaap Liabilities
Liabilities
10024000
CY2020Q4 us-gaap Liabilities
Liabilities
7720000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88318454
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59657742
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
60000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371638000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
270155000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-267000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-579000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263572000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222985000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46651000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117911000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54371000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1500000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1500000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32160000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20423000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10766000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9616000
CY2021 us-gaap Operating Expenses
OperatingExpenses
42926000
CY2020 us-gaap Operating Expenses
OperatingExpenses
30039000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41426000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-28539000
CY2021 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
9000
CY2020 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
93000
CY2021 us-gaap Interest Expense
InterestExpense
41000
CY2020 us-gaap Interest Expense
InterestExpense
39000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2020 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
231000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-379000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
738000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40611000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27516000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27514000
CY2020 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
303000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
372000
CY2020 lptx Preferred Stock Convertible Beneficial Conversion Feature
PreferredStockConvertibleBeneficialConversionFeature
9399000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40587000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37588000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85825283
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59327713
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85825283
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59327713
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27514000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
312000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-655000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40275000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28169000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-1749000
CY2020 lptx Convertible Preferred Stock Discount Beneficial Conversion Feature
ConvertiblePreferredStockDiscountBeneficialConversionFeature
9399000
CY2020 lptx Dividends Preferred Stock Accrued
DividendsPreferredStockAccrued
-372000
CY2020 lptx Conversion Of Convertible Preferred Stock Dividends To Prefunded Warrants And Common Stock
ConversionOfConvertiblePreferredStockDividendsToPrefundedWarrantsAndCommonStock
372000
CY2020 lptx Conversion Of Convertible Preferred Stock To Prefunded Warrants
ConversionOfConvertiblePreferredStockToPrefundedWarrants
8836000
CY2020 lptx Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
7087000
CY2020 lptx Stock And Prefunded Warrants Issued During Period Value
StockAndPrefundedWarrantsIssuedDuringPeriodValue
48276000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
348000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-655000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2572000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27514000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46651000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46651000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
993000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021 lptx Stock And Prefunded Warrants Issued During Period Value
StockAndPrefundedWarrantsIssuedDuringPeriodValue
96828000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
312000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3686000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2021 us-gaap Profit Loss
ProfitLoss
-40587000
CY2020 us-gaap Profit Loss
ProfitLoss
-27514000
CY2021 us-gaap Depreciation
Depreciation
29000
CY2020 us-gaap Depreciation
Depreciation
34000
CY2021 lptx Amortization Of Contract Assets
AmortizationOfContractAssets
135000
CY2020 lptx Amortization Of Contract Assets
AmortizationOfContractAssets
135000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
392000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
499000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3686000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2572000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-379000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
738000
CY2021 lptx Fair Value Adjustment Of Restricted Stock Liability
FairValueAdjustmentOfRestrictedStockLiability
-204000
CY2020 lptx Fair Value Adjustment Of Restricted Stock Liability
FairValueAdjustmentOfRestrictedStockLiability
45000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
639000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263572000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114916000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-774000
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-11000
CY2020 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
36000
CY2021 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
1159000
CY2020 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
-117000
CY2020 lptx Increase Decrease In Contract Acquisition Cost
IncreaseDecreaseInContractAcquisitionCost
270000
CY2021 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-209000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3900000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2601000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1500000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1500000
CY2021 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-406000
CY2020 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-474000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-597000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35157000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25957000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25000
CY2021 lptx Proceeds From Issuance Of Common Stock September2021 Public Offering
ProceedsFromIssuanceOfCommonStockSeptember2021PublicOffering
97222000
CY2020 lptx Proceeds From Issuance Of Common Stock In Connection With Public Offering
ProceedsFromIssuanceOfCommonStockInConnectionWithPublicOffering
48518000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
993000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
348000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
184000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1906000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98035000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73997000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
62845000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48180000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52071000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3891000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52071000
CY2021 lptx Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
210000
CY2021 lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
323000
CY2020 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
303000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114916000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2021 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2021Q4 us-gaap Business Combination Contingent Consideration Asset Current
BusinessCombinationContingentConsiderationAssetCurrent
1189000
CY2020Q4 us-gaap Business Combination Contingent Consideration Asset Current
BusinessCombinationContingentConsiderationAssetCurrent
73000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2020 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
231000
CY2019Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
185000
CY2020 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
231000
CY2020 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
331000
CY2020 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-12000
CY2020Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
73000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2021 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
111000
CY2021 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
1000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount.</p>
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
51116000
CY2020 lptx Restricted Stock Liability
RestrictedStockLiability
204000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
204000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
51116000
CY2020Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
345000
CY2021Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112726000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
51116000
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
190000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
161000
CY2020 us-gaap Depreciation
Depreciation
34000
CY2021 lptx Upfront Fees
UpfrontFees
3000000
CY2021Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
270000
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
135000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
135000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000
CY2021 us-gaap Depreciation
Depreciation
29000
CY2020 lptx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3000000
CY2020 lptx Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
1500000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1500000
CY2021 lptx Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
1500000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
226000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
226000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.33
CY2021 lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2499000
CY2020Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
795000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
181000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
255000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2686000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1697000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2747000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
469000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
423000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
549000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
442000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
37000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
479000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
469000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
60386157
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4024566
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.48
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2662500
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.10
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
32778
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.53
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
260435
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.95
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6393853
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.29
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1961000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2482650
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.19
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2292
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
348593
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.17
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8525618
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.48
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7673000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5421641
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.83
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M20D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4074000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8525618
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.48
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7673000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.37
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6764
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6694
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0082
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0066
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y9M25D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10M6D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3921000
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
204000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3686000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2776000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39155000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28699000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1456000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1183000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40611000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27516000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-37000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
40000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-37000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
40000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
13000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-42000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
13000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-42000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.070
CY2021 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.039
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.060
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.005
CY2021 lptx Effective Income Tax Rate Reconciliation Dta Write Off.
EffectiveIncomeTaxRateReconciliationDtaWriteOff.
0.000
CY2020 lptx Effective Income Tax Rate Reconciliation Dta Write Off.
EffectiveIncomeTaxRateReconciliationDtaWriteOff.
-0.702
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.306
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.366
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.012
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
729000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
455000
CY2021Q4 lptx Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
1004000
CY2020Q4 lptx Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
1168000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4671000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3759000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
212000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
228000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
11246000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8959000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
41207000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
33711000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
66241000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53848000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
66082000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53669000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
159000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
179000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10068000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12413000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27514000
CY2020 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
303000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
372000
CY2020 lptx Preferred Stock Convertible Beneficial Conversion Feature
PreferredStockConvertibleBeneficialConversionFeature
9399000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40587000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-37588000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85825283
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59327713
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2021 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants And Penny Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrantsAndPennyWarrants
24930483
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44916898
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
43133276
CY2021Q4 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
5680000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
247000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
195000

Files In Submission

Name View Source Status
0001104659-22-032638-index-headers.html Edgar Link pending
0001104659-22-032638-index.html Edgar Link pending
0001104659-22-032638.txt Edgar Link pending
0001104659-22-032638-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lptx-20211231.xsd Edgar Link pending
lptx-20211231x10k.htm Edgar Link pending
lptx-20211231x10k_htm.xml Edgar Link completed
lptx-20211231xex10d27.htm Edgar Link pending
lptx-20211231xex21d1.htm Edgar Link pending
lptx-20211231xex23d1.htm Edgar Link pending
lptx-20211231xex31d1.htm Edgar Link pending
lptx-20211231xex32d1.htm Edgar Link pending
lptx-20211231_cal.xml Edgar Link unprocessable
lptx-20211231_def.xml Edgar Link unprocessable
lptx-20211231_lab.xml Edgar Link unprocessable
lptx-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending